Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma
10.46883/2023.25920992
Saved in:
Main Authors: | Daniel V. T. Catenacci, Yoon-Koo Kang, Hope E. Uronis, Keun-Wook Lee, Matthew C. H. Ng, Peter C. Enzinger, Se Hoon Park, Philip J. Gold, Jill Lacy, Howard S. Hochster, Sang Cheul Oh, Yeul Hong Kim, Kristen A. Marrone, Ronan J. Kelly, Rosalyn A. Juergens, Jong Gwang Kim, Thierry Alcindor, Sun Jin Sym, Eun-Kee Song, Cheng Ean Chee, Yee Chao, Sunnie Kim, Do-Youn Oh, Jennifer Yen, Justin I. Odegaard, Errin Lagow, Daner Li, Jichao Sun, Patrick Kaminker, Paul A. Moore, Minori Koshiji Rosales, Haeseong Park |
---|---|
Other Authors: | MEDICINE |
Format: | Article |
Published: |
MJH Life Sciences
2023
|
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/239260 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4
by: Kim, YN, et al.
Published: (2023) -
A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)
by: Lee, Yong Jae, et al.
Published: (2021) -
Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer
by: Ngoi, NYL, et al.
Published: (2021) -
PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report
by: Sachdeva, Manavi, et al.
Published: (2021) -
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
by: Harrington K.J.
Published: (2023)